Mendel.ai is a life science company offering an artificial intelligence platform to aid clinical experts improve their clinical cancer research that is headquartered in San Jose, California and was founded in 2016 by Karim Galil, Ruchi Deshpande, and Wael Salloum. The AI platform is named "Mendel Brain" and is made to aid clinicians in all aspects of clinical trial research. The company claims Mendel Brain allows querying of medical records, skimming through scientific papers, help with feasibility surveys, and augmenting screening processes.
On November 2, 2016 Mendel.ai announced receiving a convertible note from SOSV and IndieBio for an undisclosed amount.
On July 1, 2017 Mendel.ai announced raising $2 million in funding from DCM Ventures, Bootstrap Labs, and Launch Capital. The company plans on using their seed funding to begin implementing their Mendel Brain product in hospitals and cancer genomics companies. At the time of announcing their seed funding, Mendel.ai began working with the Comprehensive Blood & Cancer Center (CBCC) in Bakersfield, California to help the center match patients with doctors and clinical trials for treating cancer.
John Lee, Partner at JAZZ Venture Partners on Patientless Podcast #007